Investment Thesis
Voyager Therapeutics is a pre-commercial biotech company in severe financial distress with collapsing revenues (-49.5% YoY), massive operating losses (-$30.3M), and a burn rate of $33.4M annually that will exhaust the $43.3M cash position within approximately 15 months without revenue growth or capital raises. The fundamentals show deteriorating business momentum with no pathway to profitability visible in current financial trajectory.
Strengths
- Strong balance sheet with $173.7M stockholders' equity and minimal debt
- Excellent liquidity position with 8.42x current ratio providing short-term financial stability
- Asset-light operations with minimal capex ($14K) reducing capital requirements
Risks
- Severe revenue collapse of 49.5% YoY indicating failed commercialization or lost partnerships
- Unsustainable cash burn of $33.4M annually with only ~15 months of runway at current rate
- Massive operating losses (-$1,167% margin) with no profitability pathway or positive unit economics demonstrated
- High dilution risk requiring additional capital raises to continue operations
- Biotech execution risk with uncertain pipeline outcomes and no visible revenue recovery trajectory
Key Metrics to Watch
- Cash balance and monthly burn rate (critical survival metric with <18 month runway)
- Revenue trend stabilization and growth (currently in free fall)
- Operating cash flow management and path to cash flow breakeven
- Clinical pipeline advancement and partnership announcements (potential capital sources)
Financial Metrics
Revenue
2.6M
Net Income
-27.9M
EPS (Diluted)
$-0.47
Free Cash Flow
-33.4M
Total Assets
219.3M
Cash
43.3M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-1,167.4%
Net Margin
-1,077.4%
ROE
-16.1%
ROA
-12.7%
FCF Margin
-1,289.4%
Balance Sheet & Liquidity
Current Ratio
8.42x
Quick Ratio
8.42x
Debt/Equity
0.00x
Debt/Assets
20.8%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-08T08:45:17.773803 |
Data as of: 2026-03-31 |
Powered by Claude AI